2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-168167
    BuChE-IN-14 38455-99-1 98%
    BuChE-IN-14 is a novel compound that selectively inhibits acetylcholinesterase (AChE) activity. BuChE-IN-14 showed a concentration-dependent inhibitory effect on AChE in rat brain in vitro experiments. BuChE-IN-14 can increase the extracellular acetylcholine (ACh) concentration in the rat hippocampus and striatum at a certain dose. BuChE-IN-14 may help improve memory impairment caused by cholinergic dysfunction.
    BuChE-IN-14
  • HY-168169
    hMAO-B-IN-10 98%
    hMAO-B-IN-10 (compound 7) is an inhibitor of MAO-A/B with IC50 of 424.1 nM and 177.9 nM, respectively. hMAO-B-IN-10 exerts a certain neuroprotective effect in MPTP (HY-15608)-induced mouse PD model..
    hMAO-B-IN-10
  • HY-168177
    ROS-IN-3 98%
    ROS-IN-3 (compound x38) is a ROS inhibitor. ROS-IN-3 can be used in neuro-related research.
    ROS-IN-3
  • HY-168214
    Kv7.2/Kv7.3 agonist 1 2315450-35-0 98%
    Kv7.2/Kv7.3 agonist 1 (Compound 16) is an orally active agonist for KV7.2/7.3 channel (KCNQ2/3) with an EC50 of 1.03 μM. Kv7.2/Kv7.3 agonist 1 exhibits analgesic efficacy in mice chronic constriction injury (CCI) model and mice Streptozotocin (HY-13753)-induced diabetic peripheral neuropathic pain (DPNP) model, with ED50 of 12.02 and 9.63 mg/kg.
    Kv7.2/Kv7.3 agonist 1
  • HY-168240
    NMDAR antagonist 2 98%
    NMDAR antagonist 2 (compound 3I) is a CNS penetrant NMDAR antagonist with the IC50 of 4.42 μM and 214.75 μM for hGluN1/hGluN2A at −60 mV or 40 mV membrane potentials, respectively. NMDAR antagonist 2 can reduce hippocampal damage.
    NMDAR antagonist 2
  • HY-168264
    MC1 98%
    MC1 is a potent NLRP3 inhibitor with a KD value of 19.3 nM. MC1 shows no cytotoxicity. MC1 ameliorates cognitive deficits without eliciting adverse effects and shows an absence of hepatotoxicity. MC1 has the potential for the research of Alzheimer's disease (AD).
    MC1
  • HY-168273
    Glutaminyl cyclases-IN-2 98%
    Glutaminyl cyclases-IN-2 (compound 27) is a potent inhibitor of glutaminyl cyclase, with the IC50 of 0.08 μM. Glutaminyl cyclases-IN-2 plays an important role in cancer research.
    Glutaminyl cyclases-IN-2
  • HY-168301
    CL-13 98%
    CL-13 is a butyrylcholinesterase (BChE) inhibitor, with an IC50 of 1.15 μM, and a selectivity index (SI) of 9.2 for acetylcholinesterase. CL-13 shows antioxidant activity in SH-SY5Y cells (DPPH EC50 = 47.01 μM) and has the ability to chelate metals involved in Aβ aggregation and/or oxidative stress, showing no neurotoxicity at 50 μM. CL-13 can reverse cognitive impairment caused by scopolamine (HY-N0296) without affecting the mice's motor skills.
    CL-13
  • HY-168320
    N-Stearoyltyrosine 57993-25-6 98%
    N-Stearoyltyrosine (N-(1-Oxooctadecyl)-L-tyrosine) is an analog of Anandamide (HY-10863). N-Stearoyltyrosine exhibits neuroprotective efficacy in gerbils ischemia-reperfusion model through protection in the CA1 region of the hippocampus. N-Stearoyltyrosine inhibits the free radicals production and improves antioxidant capacity. N-Stearoyltyrosine inhibits the IR-induced apoptosis.
    N-Stearoyltyrosine
  • HY-168325
    UP12 443353-87-5 98%
    UP12 enhances the activity of ATPase, and activates valosin-containing protein (VCP) with an EC50 of 1.24 μM.
    UP12
  • HY-168333
    5-HT6 inverse agonist 1 2727088-38-0 98%
    5-HT6 inverse agonist 1 (Compound 33) is an antagonist for 5-HT6 receptor with a Ki of 23 nM and a Kb of 6.62 nM. 5-HT6 inverse agonist 1 inhibits the 5-HT6R mediated Cdk5 and mTOR signaling pathway. 5-HT6 inverse agonist 1 reduces tactile hypersensitivity in spinal nerve ligation (SNL)-induced rat model.
    5-HT6 inverse agonist 1
  • HY-168334
    5-HT2C agonist-4 2730085-33-1 98%
    5-HT2C agonist-4 (Compound 3i) is an agonist for 5-HT2C receptor with an EC50 of 5.7 nM. 5-HT2C agonist-4 reduces locomotor activity in the zebrafish larval model.
    5-HT2C agonist-4
  • HY-168351
    Fluorphine 6440-42-2 98%
    Fluorphine is an analogue of Brorphine and can bind to μ-opioid receptor (MOR) (Ki: 12.5 nM). Fluorphine has GTPγS binding (EC50: 75 nM) and βarrestin 2 recruitment (EC50: 377 nM) activity. Fluorphine induces respiratory depressant effects.
    Fluorphine
  • HY-168357
    Cannabiphorol 55824-14-1 98%
    Cannabiphorol (compound 4d) is a rare cannabinoid closely related to cannabinol. Cannabiphorol has the potential for the research of synergistic effects when combined with other cannabinoids.
    Cannabiphorol
  • HY-168459
    MAGL-IN-21 98%
    MAGL-IN-21 (Compound (S)-6) is a selective inhibitor for monoacylglycerol lipase (MAGL) with an IC50 of 1.59 nM.
    MAGL-IN-21
  • HY-168466
    Anti-neuroinflammation agent 2 3040102-76-6 98%
    Anti-neuroinflammation agent 2 (compound 4) demonstrates anti-neuroinflammatory and antibacterial activities, with IC50 values of 3.06 µM for TNF-α and 4.31 µM for IL-6, alongside EC50 values ranging from 0.87 to 3.16 µM against Gram-positive bacteria.
    Anti-neuroinflammation agent 2
  • HY-168494
    GluN2A Allosteric modulator 1 98%
    GluN2A Allosteric modulator 1 (Compound 11) is an orally active, BBB-penetrable and highly selective GluN2A negative allosteric modulator. GluN2A Allosteric modulator 1 has IC50 values of 0.042 μM and 13 μM for GluN2A and GluN2B, respectively. GluN2A Allosteric modulator 1 can be used for the research of nervous system diseases.
    GluN2A Allosteric modulator 1
  • HY-168508
    PB200 98%
    PB200 is an HDAC6 inhibitor with an IC50 value of 1.97 nM. PB200 demonstrates significant antidepressant effects by restoring abnormal HDAC6 expression levels and alleviating neuroinflammation.
    PB200
  • HY-168562
    σ1 Receptor ligand 1 98%
    σ1 Receptor ligand 1 (compound 5I) is a σ1 receptor ligand with a Ki of 3.9 nM. σ1 Receptor ligand 1 has a high plasma protein binding (89%) and promising metabolic stability in the presence of mouse liver microsomes and NADPH. σ1 Receptor ligand 1 can be utilized in neurological and cancer research.
    σ1 Receptor ligand 1
  • HY-168563
    BuChE-IN-15 98%
    BuChE-IN-15 (compound D12) is a selective BuChE/FAAH dual inhibitor with and show IC50 values of 81 and 400 nM for hBuChE and hFFAH, respectively. BuChE-IN-15 possesses good BBB penetration, and shows neuroprotection.BuChE-IN-15 can be used for study of Alzheimer.
    BuChE-IN-15
Cat. No. Product Name / Synonyms Application Reactivity